Provider and patient correlates of provider decisions to recommend HCV treatment to HIV Co-infected patients

Journal of the International Association of Physicians in AIDS Care

Volumn 11, Issue 4, 2012, Pages 245-251

  Wagner, Glenn ^a   Osilla, Karen Chan ^a   Garnett, Jeffrey ^a   Ghosh Dastidar, Bonnie ^a   Bhatti, Laveeza ^b   Witt, Mallory ^c   Goetz, Matthew Bidwell ^d  

^a RAND CORPORATION   (United States)

^b AIDS HEALTHCARE FOUNDATION   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

hepatitis C; provider treatment decision making; treatment readiness

Indexed keywords

ADULT; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIXED INFECTION; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RACE DIFFERENCE; UNITED STATES; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; COINFECTION; CROSS-SECTIONAL STUDIES; DECISION MAKING; DEPRESSION; DIRECTIVE COUNSELING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HIV INFECTIONS; HUMANS; LOS ANGELES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; SEX FACTORS; WORKLOAD;

EID: 84865091292     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109712444163     Document Type: Article

References (43)

1. DiMartino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001 ; 34 (6). 1193-1199 (Pubitemid 33096592)
2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis. 2001 ; 32 (3). 492-497 (Pubitemid 32173638)
3. Cacoub P, Geffray L, Rosenthal E, et al. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases in 1995 and 1997. Clin Infect Dis. 2001 ; 32 (3). 1207-1214 (Pubitemid 32381124)
4. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007 ; 14 (2). 107-115 (Pubitemid 46146705)
5. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004 ; 38 (1). 128-133 (Pubitemid 38045883)
6. Berenguer J, Bellon JM, Miralles P, et al. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat. 2007 ; 14 (12). 859-869 (Pubitemid 350211409)
7. Rauch A, Egger M, Reichen J, Furrer H, Swiss HIV. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated-interferon-alpha plus ribavirin. J Acquir Immune Defic Syndr. 2005 ; 38 (2). 238-240 (Pubitemid 40189334)
8. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immnunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003 ; 36 (1). 97-100 (Pubitemid 36099103)
9. Taylor LE, Costello T, Alt E, et al. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS. 2002 ; 16 (12). 1700-1701 (Pubitemid 34921123)
10. Fultz SL, Justice AC, Butt AA, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis. 2003 ; 36 (8). 1039-1046 (Pubitemid 36513290)
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterfeon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 ; 351 (5). 438-450 (Pubitemid 38988593)
12. Chung RT, Andersen J, Volberding P, et al. Peginterfeon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 ; 351 (5). 451-459 (Pubitemid 38988594)
13. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA. 2004 ; 292 (23). 2839-2848 (Pubitemid 39628231)
14. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004 ; 18 (13). 27-36
15. Bräu N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-co-infection with interferon 2b+ full-course vs. 16-week delayed Ribavirin. Hepatology. 2004 ; 39 (4). 989-998 (Pubitemid 38428938)
16. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004 ; 18 (1). 75-79 (Pubitemid 38402320)
17. Lane HC, Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymtomatic human immuno-deficiency virus (HIV) infection: a randomized, placebo-controlled trial. Ann Intern Med. 1990 ; 112 (11). 805-811 (Pubitemid 20182780)
18. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004 ; 18 (1). 1-12 (Pubitemid 38402312)
19. Management of Hepatitis C. Gastroenterology. 2002 ; 123 (6). 2082-2099
20. GishRG. Controversies in hepatitis C therapy: HCV-the case for selective treatment. www.medscape.com. Accessed January 13, 2010.
21. Schaefer E, Chung RT. HIV and HCV coinfection: where are we in 2010?. Curr Hepatitis Rep. 2010 ; 9: 155-160
22. Wong JB, Bennet WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA. 1998 ; 280 (24). 2088-2093 (Pubitemid 29014067)
23. LaBrecqueDR. Controversies in hepatitis C therapy: HCV-virtually all patients should be treated. www.medscape.com. Accessed November 24, 2009.
24. Ogawa LF, Bova C. HCV treatment decision-making substance use experiences and Hepatitis C treatment decision-making among HIV/HCV coinfected patients. Subst Use Misuse. 2009 ; 44 (7). 915-933
25. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv. 2006 ; 57 (4). 570-572
26. Cacoub P, Rosenthal E, Halfon P, et al. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat. 2006 ; 13 (10). 678-682 (Pubitemid 44401196)
27. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001 ; 34 (1). 188-193 (Pubitemid 32591499)
28. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002 ; 67 (2). 117-123 (Pubitemid 34722399)
29. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003 ; 37 (2). 443-451 (Pubitemid 36152544)
30. Seal KH, Currie SL, Shen H, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: Does a history of injection drug use matter?. J Clin Gastroenterol. 2007 ; 41 (2). 199-205 (Pubitemid 46148663)
31. Huckans MS, Loftis JM, Blackwell AD, Linke A, Hauser P. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders. Subst Abuse Treat Prev Policy. 2007 ; 2: 4
32. Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-monoinfected and HIV/HCV co-infected injection drug users. AIDS. 2005 ; 19 (suppl 3). S179 - S189
33. Wagner GJ, Ryan G, Chan Osilla K, Bhatti L, Goetz M, Witt M. Treat early or wait and monitor? A qualitative analysis of provider HCV treatment decision making in the context of HIV co-infection. AIDS Patient Care STDs. 2009 ; 23 (9). 715-725
34. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis. 2005 ; 40 (suppl 5). S313 - S320
35. Meredith LS, Yano EM, Hickey SC, Sherman SE. Primary care provider attitudes are associated with smoking cessation counseling and referral. Med Care. 2005 ; 43 (9). 929-944
36. Osilla KC, Wagner G, Garnett J, Bhatti L, Goetz M, Witt M. Patient and provider characteristics associated with the decision of HIV co-infected patients to start Hepatitis C treatment. AIDS Patient Care STDS. 2011 ; 25 (9). 533-538
37. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med. 2010 ; 153 (4). 231-239
38. Torriani F, Soriano F. Chronic hepatitis C in HIV-infected individuals. AIDS Review. 2000 ; 2: 168-177 (Pubitemid 33121187)
39. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005 ; 43 (9 suppl). 40-52
40. Conjeevaram H, Fried M, Jeffers L, et al. Peginterferon and ribavirin treatment in African American patients and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006 ; 131 (2). 470-477 (Pubitemid 44142464)
41. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 ; 461 (7262). 399-401
42. Satapathy SK, Lingisetty CS, Proper S, et al. Equally poor outcomes to pegylated interferon-based therapy in African American and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol. 2010 ; 44 (2). 140-145
43. Liu-Young G, Kozal MJ. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDs. 2008 ; 22 (6). 449-457